[Federal Register Volume 85, Number 71 (Monday, April 13, 2020)]
[Notices]
[Page 20508]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-07706]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive Patent License: AAV Mediated 
Exendin-4 Gene Transfer to Salivary Glands To Protect Subjects From 
Diabetes or Obesity

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Institute of Diabetes and Digestive and Kidney 
Disease and National Institute of Dental and Craniofacial Research, 
institutes of the National Institutes of Health, Department of Health 
and Human Services, are contemplating the grant of an Exclusive Patent 
License to practice the inventions embodied in the United States, 
European and Canadian Applications listed in the Supplementary 
Information section of this notice to Kriya Therapeutics, Inc., located 
in Palo Alto, California, USA.

DATES: Only written comments and/or applications for a license which 
are received by the National Institute of Diabetes and Digestive and 
Kidney Disease's Technology Advancement Office on or before April 28, 
2020 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, 
and comments relating to the contemplated an Exclusive Patent License 
should be directed to: Vladimir Knezevic, MD, (Senior) Advisor for 
Commercial Evaluation, Technology Advancement Office, Building 12A, 
Room 3011, Bethesda, MD 20817-5632 (for business mail), Telephone: 
(301)-435-5560; Email: [email protected].

SUPPLEMENTARY INFORMATION: 

Intellectual Property

    I. U.S. Pat: 9,511,103 issued 2016-12-06, entitled ``AAV mediated 
exendin-4 gene transfer to salivary glands to protect subjects from 
diabetes or obesity'' (HHS Reference Number E-142-2011-0-US-05).
    II. U.S. Divisional Pat: 10,300,095 issued 2019-05-28, entitled 
``AAV mediated exendin-4 gene transfer to salivary glands to protect 
subjects from diabetes or obesity'' (HHS Reference Number E-142-2011-0-
US-6).
    III. European Patent National Stage: EP2709653 granted 2017-11-22, 
entitled ``AAV mediated exendin-4 gene transfer to salivary glands to 
protect subjects from diabetes or obesity'' (HHS Reference Number E-
142-2011-0EP-04), validated in Great Britain, France and Germany.
    IV. U.S. Patent Application No. 16/396,262 filed 2019-04-26, 
entitled ``AAV Mediated Exendin-4 Gene Transfer to Salivary Glands to 
Protect Subjects from Diabetes or Obesity'' (HHS Reference Number E-
142-2011-0-US-10).
    V. Canadian Application No. 2,833,623 filed 2012-04-19, entitled 
``AAV Mediated Exendin-4 Gene Transfer to Salivary Glands to Protect 
Subjects from Diabetes or Obesity'' (HHS Reference Number E-142-2011-0-
CA-03).
    The patent rights in these inventions have been assigned or 
exclusively licensed to the Government of the United States of America.
    The prospective exclusive license territory may be worldwide and in 
fields of use that may be limited to prevention and treatment of type-2 
diabetes and obesity.
    The above-listed patent portfolio covers inventions directed to 
gene therapy and specifically, expression vectors and therapeutic 
methods of using such vectors in the treatment of type-2 diabetes and 
obesity.
    This notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing. 
The prospective exclusive license may be granted unless within fifteen 
(15) days from the date of this published notice, the National 
Institute of Diabetes and Digestive and Kidney Disease receives written 
evidence and argument that establishes that the grant of the license 
would not be consistent with the requirements of 35 U.S.C. 209 and 37 
CFR part 404.
    In response to this Notice, the public may file comments or 
objections. Comments and objections, other than those in the form of a 
license application, will not be treated confidentially and may be made 
publicly available.
    License applications submitted in response to this notice will be 
presumed to contain business confidential information and any release 
of information in these license applications will be made only as 
required and upon a request under the Freedom of Information Act, 5 
U.S.C. 552.

    Dated: April 1, 2020.
Vladimir Knezevic,
Senior Advisor for Commercial Evaluation, Technology Advancement 
Office, National Institute of Diabetes and Digestive and Kidney 
Disease.
[FR Doc. 2020-07706 Filed 4-10-20; 8:45 am]
 BILLING CODE 4140-01-P